Imunon annual net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Net Income Growth & History (IMNN)
Imunon's net income was −$14.5M for fiscal 2025.
View full Imunon company overviewImunon annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$14.5M | $4.1M | — |
| 2024 | 2024-12-31 | −$18.6M | $894,735 | — |
| 2023 | 2023-12-31 | −$19.5M | $16.4M | — |
| 2022 | 2022-12-31 | −$35.9M | −$15.1M | — |
| 2021 | 2021-12-31 | −$20.8M | $714,311 | — |
| 2020 | 2020-12-31 | −$21.5M | −$4.6M | — |
| 2019 | 2019-12-31 | −$16.9M | −$5.0M | — |
| 2018 | 2018-12-31 | −$11.9M | $8.5M | — |
| 2017 | 2017-12-31 | −$20.4M | $1.7M | — |
| 2016 | 2016-12-31 | −$22.1M | $407,358 | — |
| 2015 | 2015-12-31 | −$22.5M | $3.0M | — |
| 2014 | 2014-12-31 | −$25.5M | −$17.2M | — |
| 2013 | 2013-12-31 | −$8.3M | $18.3M | — |
| 2012 | 2012-12-31 | −$26.6M | −$3.3M | — |
| 2011 | 2011-12-31 | −$23.2M | −$4.4M | — |
| 2010 | 2010-12-31 | −$18.8M | — | — |
Imunon quarterly net income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.8M | −$73,555 | — |
| Q1 2026 | 2026-03-31 | −$4.2M | −$146,527 | — |
| Q4 2025 | 2025-12-31 | −$4.2M | −$165,625 | — |
| Q3 2025 | 2025-09-30 | −$3.4M | $1.4M | — |
| Q2 2025 | 2025-06-30 | −$2.7M | $2.0M | — |
| Q1 2025 | 2025-03-31 | −$4.1M | $827,030 | — |
| Q4 2024 | 2024-12-31 | −$4.1M | $830,908 | — |
| Q3 2024 | 2024-09-30 | −$4.8M | −$1.4M | — |
| Q2 2024 | 2024-06-30 | −$4.8M | $770,848 | — |
| Q1 2024 | 2024-03-31 | −$4.9M | $661,840 | — |
| Q4 2023 | 2023-12-31 | −$4.9M | $8.3M | — |
| Q3 2023 | 2023-09-30 | −$3.5M | $2.7M | — |
| Q2 2023 | 2023-06-30 | −$5.6M | $484,072 | — |
| Q1 2023 | 2023-03-31 | −$5.6M | $4.9M | — |
| Q4 2022 | 2022-12-31 | −$13.2M | −$9.0M | — |
| Q3 2022 | 2022-09-30 | −$6.1M | −$737,746 | — |
| Q2 2022 | 2022-06-30 | −$6.0M | −$594,540 | — |
| Q1 2022 | 2022-03-31 | −$10.5M | −$4.8M | — |
| Q4 2021 | 2021-12-31 | −$4.2M | −$1.2M | — |
| Q3 2021 | 2021-09-30 | −$5.4M | $2.7M | — |
| Q2 2021 | 2021-06-30 | −$5.4M | −$105,462 | — |
| Q1 2021 | 2021-03-31 | −$5.7M | −$632,125 | — |
| Q4 2020 | 2020-12-31 | −$3.0M | $90,607 | — |
| Q3 2020 | 2020-09-30 | −$8.1M | −$2.6M | — |
| Q2 2020 | 2020-06-30 | −$5.3M | $561,580 | — |
| Q1 2020 | 2020-03-31 | −$5.1M | −$2.7M | — |
| Q4 2019 | 2019-12-31 | −$3.1M | −$8.6M | — |
| Q3 2019 | 2019-09-30 | −$5.5M | −$820,421 | — |
| Q2 2019 | 2019-06-30 | −$5.9M | $2.3M | — |
| Q1 2019 | 2019-03-31 | −$2.4M | $2.1M | — |
| Q4 2018 | 2018-12-31 | $5.5M | $9.4M | — |
| Q3 2018 | 2018-09-30 | −$4.7M | $1.0M | — |
| Q2 2018 | 2018-06-30 | −$8.2M | −$2.6M | — |
| Q1 2018 | 2018-03-31 | −$4.5M | $683,141 | — |
| Q4 2017 | 2017-12-31 | −$3.9M | $1.5M | — |
| Q3 2017 | 2017-09-30 | −$5.7M | $738,358 | — |
| Q2 2017 | 2017-06-30 | −$5.7M | −$1.1M | — |
| Q1 2017 | 2017-03-31 | −$5.2M | $556,331 | — |
| Q4 2016 | 2016-12-31 | −$5.4M | $117,411 | — |
| Q3 2016 | 2016-09-30 | −$6.4M | −$2.1M | — |
| Q2 2016 | 2016-06-30 | −$4.5M | $1.1M | — |
| Q1 2016 | 2016-03-31 | −$5.7M | $1.3M | — |
| Q4 2015 | 2015-12-31 | −$5.5M | $941,000 | — |
| Q3 2015 | 2015-09-30 | −$4.3M | $2.7M | — |
| Q2 2015 | 2015-06-30 | −$5.7M | $998,255 | — |
| Q1 2015 | 2015-03-31 | −$7.0M | −$1.6M | — |
| Q4 2014 | 2014-12-31 | −$6.5M | −$2.5M | — |
| Q3 2014 | 2014-09-30 | −$6.9M | −$2.9M | — |
| Q2 2014 | 2014-06-30 | −$6.7M | −$7.1M | — |
| Q1 2014 | 2014-03-31 | −$5.4M | −$4.8M | — |
| Q4 2013 | 2013-12-31 | −$3.9M | $4.3M | — |
| Q3 2013 | 2013-09-30 | −$4.1M | $1.9M | — |
| Q2 2013 | 2013-06-30 | $420,884 | $6.5M | — |
| Q1 2013 | 2013-03-31 | −$650,974 | $5.5M | — |
| Q4 2012 | 2012-12-31 | −$8.3M | −$2.1M | — |
| Q3 2012 | 2012-09-30 | −$6.0M | $374,957 | — |
| Q2 2012 | 2012-06-30 | −$6.1M | $839,640 | — |
| Q1 2012 | 2012-03-31 | −$6.2M | −$2.4M | — |
| Q4 2011 | 2011-12-31 | −$6.1M | — | — |
| Q3 2011 | 2011-09-30 | −$6.4M | −$1.7M | — |
| Q2 2011 | 2011-06-30 | −$6.9M | −$4.3M | — |
| Q1 2011 | 2011-03-31 | −$3.8M | — | — |
| Q3 2010 | 2010-09-30 | −$4.7M | — | — |
| Q2 2010 | 2010-06-30 | −$2.6M | — | — |
Imunon net income trends
Over the last five fiscal years, Imunon's net income increased from −$21.5M to −$14.5M, a change of $7.0M. The latest reported quarter, Q2 2026, shows −$2.8M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...